Comparison of High-Dose and Low-Dose Aspirin Plus Intravenous Immunoglobulin in the Treatment of Kawasaki Syndrome

Abstract

The efficacy of intravenous immunoglobulin (IVIG) in the treatment of Kawasaki syndrome (KS) has been unequivocally established, but questions remain concerning the proper dose of adjunctive aspirin therapy in the treatment of KS. The medical records of 72 children with KS were reviewed. All patients were treated with IVIG; 21 received 400 mg/kg/dose on 4 consecutive days and 51 received 2 g/kg as a single infusion. Seventy patients also received aspirin. Twenty-four of the 70 patients were started on high-dose aspirin (80-100 mg/kg/day) at the time of diagnosis. High-dose aspirin was given for a mean (± SE) duration of 6.1 ± 0.9 days, then switched to low-dose aspirin (3-5 mg/kg/day). Forty-six of the 70 patients were started on low-dose aspirin at the time of diagnosis and remained on low-dose aspirin for the duration of treatment. Coronary artery abnormalities were present at the time of diagnosis in 12 of 72 patients (17%), including 6 of 6 of patients (100%) with atypical KS and 6 of 66 patients (9%) with typical KS. None of the remaining 60 patients developed coronary artery abnormalities after treatment with IVIG and aspirin. The mean duration of fever after initiation of therapy was 44 ± 6 hours in patients treated with IVIG 400 mg/kg/dose on 4 consecutive days and 35 ± 5 hours in patients treated with 2 g/kg as a single infusion (p=0.3). The mean duration of fever after the initiation of therapy was 47 ± 8 hours in patients treated with high-dose aspirin compared to 34 ± 5 hours in patients treated with low-dose aspirin (p=0.13). These preliminary results indicate there is no benefit to high-dose aspirin compared to low-dose aspirin in the treatment of children with KS.

Get full access to this article

View all access options for this article.

References

1. Mason WH , Takahashi M . Kawasaki syndrome. Clin Infect Dis. 1999;28:169-187.

2. Furusho K , Kamiya T , Nakano H , et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet. 1984;2:1055-1058.

3. Nagashima M , Matsushima M , Matsuoka H , et al. High-dose gammaglobulin therapy for Kawasaki disease. J Pediatr. 1987;110:710-712.

4. Newburger JW , Takahashi M , Burns JC , et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315:341-347.

5. Newburger JW , Takahashi M , Beiser AS , et al. A single intravenous infusion of gamma globulin compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324:1633-1639.

6. Dajani AS , Taubert KA , Gerber MA , et al. Diagnosis and therapy of Kawasaki disease in children. Circulation. 1993;87:1776-1780.

7. Oberhoffer R , Lang D , Feilen K . The diameter of coronary arteries in infants and children without heart disease. Eur J Pediatr. 1989;149:144-145.

8. Arjunan K , Daniels SR , Meyer RA , et al. Coronary artery caliber in normal children and patients with Kawasaki disease but without aneurysms: an echocardiographic and angiocardiographic study. J Am Coll Cardiol. 1986;8:1119-1124.

9. Koren G , Rose V , Lavi S , Rowe R . Probable efficacy of high-dose salicylates in reducing coronary involvement in Kawasaki disease. JAMA. 1985;254:767-769.

10.

10. Kato H , Koike S , Yokoyama T . Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics. 1979;63:175-179.

11.

11. Ichida F , Fatica NS , Engle ME , et al. Coronary artery involvement in Kawasaki syndrome in Manhattan, New York: risk factors and role of aspirin. Pediatrics. 1987;80:828-835.

12.

12. Terai M , Shulman ST . Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr. 1997;131:888-893.

13.

13. Melish ME , Takahashi M , Shulman S , et al. Comparison of low dose aspirin vs high dose aspirin as an adjunct to intravenous gamma globulin in the treatment of Kawasaki syndrome [abstract]. Pediatr Res. 1992;31:170A-170A.